Tifcemalimab

DB18914InvestigationalProtein Based Therapies

Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer...

Mechanism: Pharmacologically active on B- and T-lymphocyte attenuator
Curator reviewed
Also known as: Icatolimab · Immunoglobulin g4, anti-(human b and t lymphocyte attenuator (btla)) (human-mus musculus monoclonal js004 .gamma.4-chain), disulfide with human-mus musculus monoclonal js004 .kappa.-chain, dimer
Code names: JS004

Resolves to

Compound

UNIID40H7X1YZ0CAS2236068-83-8

Targets

Q7Z6A9BTLA

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

19Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tifcemalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account